Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Today, we dig into Biohaven’s plans and see Humira biosimilar prescriptions shoot up.
The need-to-know this morning
- Intra-Cellular Therapies reported positive results from a late-stage clinical trial seeking to expand the use of its antipsychotic medicine Caplyta to patients with major depressive disorder.
- Johnson & Johnson reported first-quarter adjusted earnings of $2.71 per share on total revenue of $21.38 billion — results that were mostly in line with analyst forecasts. The diversified health care giant made a small upward change to its 2024 outlook.
Biohaven’s data delay degrades stock price
Shares fell 16% yesterday after the company offered investors a double dose of confusing updates about BHV-1300, a closely followed drug designed to remove harmful proteins from the body, in this case an autoantibody called IgG that is implicated in a host of autoimmune diseases.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect